Updated on 13 March 2013
We conduct programs and workshops on good clinical practices and ethical practice. We have also developed tools that help protect patient safety and help patients be informed participants in clinical trials. My favorite tool is the "Speaking Book;" these books translate the complexity of clinical trials into language that anyone can understand, using a lot of illustrations, and help patients know if they are part of trials what their rights are. These speaking books come in a number of languages and we use these books in India and in Asia. These books were developed by Pfizer with the help of some partner organizations. We are excited about these. They are very simple and straightforward and help patients [enrolling in clinical trials] understand what they are going into.
A couple of years ago, Pfizer established an Emerging Markets division. This shines a light on the importance of the region and on the unique needs that come up in countries like India and it allows us an opportunity to focus on them and meet these unique needs. I think this is a great prospect and we have made great progress in the space. It reaffirms our commitment to the emergent market space.
In terms of R&D and clinical development, where does India stand for Pfizer?
We are very committed to India. We have been in the country for as long as I have been on earth, since the 1950's. We have very deep roots here and a commitment to delivering important innovations here. The business commitment and the commitment to the community, to helping to improve health, is one of the exciting parts of being at Pfizer for me. The desire to work not just on our work but integrate into community to understand what challenges are and to try to meet them with all the other stakeholders -- to work with public-private partnerships to help build collaborations -- that's part of the way we like to operate here in India. We are always open to working and collaborating here in India to drive innovation and to make sure patients have access to our medicines.
Pfizer is one of the partners of TransCelerate. How is Pfizer contributing to that?
TransCelerate is such an exciting and necessary option for industry. It was formed based on the belief that as industry leaders, these 10 companies [who are TransCelerate partners], we do a lot of things alone that would be more effective if we do them together. TransCelerate was formed to help us identify some areas that were low-hanging fruits. The 10 companies have agreed to contribute resources and expertise to make that happen. So this is an action-oriented group, we have workstreams that intend to pull projects together and work on these projects to improve clinical trial conduct. The workstreams are forming at this moment and moving forward.
In 2012, Pfizer's clinical trial for several drugs had seen ups and downs. What was the reason for that? For instance J&J, Pfizer halted the phase III trial of an investigational Alzheimer's therapy.